explore -WSS

explore

author：hotspot 2025-09-27 13:10:18 - browse：4

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LEXINGTON, Mass. — New obesity drugs like Wegovy and Zepbound are currently taken once a week, indefinitely. But what if they could be taken once a year instead, like a vaccine?

That’s a question that Novo Nordisk, the pharma company behind Wegovy, is exploring as it faces increased competition from other drugmakers aiming to develop similar GLP-1-based treatments for obesity.

“We have a very early think tank on: what would it take us, from a technology point of view and from an ecosystem point of view, to make long-lasting GLP-1 molecules?” Marcus Schindler, Novo’s chief scientific officer, said in an interview with STAT Wednesday. “Could we think about vaccine-like properties, where imagine you had, once a year, an injection with an equivalent of a GLP-1 that really helps you to maintain weight loss and have cardiovascular benefits?”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： 3 questions for the future of Biden's cancer moonshot

hotspot

WSS

Analysis of telehealth claims data suggest service duplication

New Covid vaccine is recommended for everyone 6 months or older

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

Physician executives need more than on

Regeneron agrees to White House price limits on anti

Wikipedia

explore

explore

FDA approval of Sarepta Duchenne genetic therapy gives me hope

When women are denied an abortion, their children fare worse than peers

In Memoriam: Notable people who died in 2023

Will the IRA bring competition to the biologics market?

Hepatitis C has a cure — but many Americans still lack access to it

Chemotherapy drug shortage eases slightly but still widespread

United colonoscopy coverage change 'may cost lives,' doctors say

What to expect at HLTH 2023, the health care industry conference

DIEP, the 'gold standard' of breast reconstruction, is under threat

Hospitals consider fixing cancer drug shortages on their own

explore

How medical schools plan to diversify without affirmative action

Chan Zuckerberg Biohub Chicago to focus on inflammation

Hospitals consider fixing cancer drug shortages on their own

Walmart eyes Medicare Advantage provider ChenMed

Private equity could exacerbate cardiology's overuse problem, experts fear

Acelyrin, a rare IPO success, stumbles in its first big test

hotspot

Wikipedia

Wikipedia

knowledge